Combination therapy of 15-epi-lipoxin a4 with antibiotics protects mice from escherichia coli-induced sepsis

Critical Care Medicine

Volumn 42, Issue 4, 2014, Pages

  Ueda, Tomomi ^a   Fukunaga, Koichi ^a   Seki, Hiroyuki ^a   Miyata, Jun ^a   Arita, Makoto ^b   Miyasho, Taku ^c   Obata, Toru ^d   Asano, Koichiro ^e   Betsuyaku, Tomoko ^a   Takeda, Junzo ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c RAKUNO GAKUEN UNIVERSITY   (Japan)

^d SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^e TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

anti inflammatory lipid mediators; combination drug therapy; lipoxin A4; mortality; peritonitis; sepsis

Indexed keywords

15 EPI LIPOXIN A4; CEFTAZIDIME; ENDOTOXIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; LIPOXIN A; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PERITONEAL DIALYSIS FLUID; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GROWTH; BACTERIAL LOAD; CELL POPULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG POTENTIATION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; EX VIVO STUDY; EXPERIMENTAL STUDY; LEUKOCYTE DIFFERENTIAL COUNT; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PERITONEUM MACROPHAGE; PERITONITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SURVIVAL RATE;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CEFTAZIDIME; DRUG THERAPY, COMBINATION; ESCHERICHIA COLI INFECTIONS; INFLAMMATION MEDIATORS; LIPOXINS; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; PERITONITIS; SEPSIS;

EID: 84897083849     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000000162     Document Type: Article

References (42)

1. Bone RC: Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 1996; 24:1125-1128
2. Lagu T, Rothberg MB, Shieh MS, et al: Hospitalizations, costs, and outcomes of severe sepsis in the United States 2003 to 2007. Crit Care Med 2012; 40:754-761
3. Levy MM, Dellinger RP, Townsend SR, et al; Surviving Sepsis Campaign: The Surviving Sepsis Campaign: Results of an international guideline-based performance improvement program targeting severe sepsis. Crit Care Med 2010; 38:367-374
4. Friedman G, Silva E, Vincent JL: Has the mortality of septic shock changed with time. Crit Care Med 1998; 26:2078-2086
5. Horn DL, Opal SM, Lomastro E: Antibiotics, cytokines, and endotoxin: A complex and evolving relationship in gram-negative sepsis. Scand J Infect Dis Suppl 1996; 101:9-13
6. Sprung CL, Annane D, Keh D, et al; CORTICUS Study Group: Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358:111-124
7. Annane D, Bellissant E, Bollaert PE, et al: Corticosteroids in the treatment of severe sepsis and septic shock in adults: A systematic review. JAMA 2009; 301:2362-2375
8. Bannenberg GL, Chiang N, Ariel A, et al: Molecular circuits of resolution: Formation and actions of resolvins and protectins. J Immunol 2005; 174:4345-4355
9. Serhan CN, Chiang N: Endogenous pro-resolving and anti-infammatory lipid mediators: A new pharmacologic genus. Br J Pharmacol 2008; 153(Suppl 1):S200-S215
10. Spite M, Norling LV, Summers L, et al: Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 2009; 461:1287-1291
11. Seki H, Fukunaga K, Arita M, et al: The anti-infammatory and prore-solving mediator resolvin E1 protects mice from bacterial pneumonia and acute lung injury. J Immunol 2010; 184:836-843
12. Serhan CN: Lipoxins and aspirin-triggered 15-epi-lipoxins are the frst lipid mediators of endogenous anti-infammation and resolution. Prostaglandins Leukot Essent Fatty Acids 2005; 73:141-162
13. Mitchell S, Thomas G, Harvey K, et al: Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of infammation: Stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. J Am Soc Nephrol 2002; 13:2497-2507
14. Chiang N, Arita M, Serhan CN: Anti-infammatory circuitry: Lipoxin, aspirin-triggered lipoxins and their receptor ALX. Prostaglandins Leukot Essent Fatty Acids 2005; 73:163-177
15. Jin SW, Zhang L, Lian QQ, et al: Posttreatment with aspirin-triggered lipoxin A4 analog attenuates lipopolysaccharide-induced acute lung injury in mice: The role of heme oxygenase-1. Anesth Analg 2007; 104:369-377
16. Fukunaga K, Kohli P, Bonnans C, et al: Cyclooxygenase 2 plays a pivotal role in the resolution of acute lung injury. J Immunol 2005; 174:5033-5039
17. Levy BD, Lukacs NW, Berlin AA, et al: Lipoxin A4 stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism. FASEB J 2007; 21:3877-3884
18. Walker J, Dichter E, Lacorte G, et al: Lipoxin a4 increases survival by decreasing systemic infammation and bacterial load in sepsis. Shock 2011; 36:410-416
19. Eisen DP, Reid D, McBryde ES: Acetyl salicylic acid usage and mortality in critically ill patients with the systemic infammatory response syndrome and sepsis. Crit Care Med 2012; 40:1761-1767
20. Christ WJ, Asano O, Robidoux AL, et al: E5531, a pure endotoxin antagonist of high potency. Science 1995; 268:80-83
21. Obata T, Nomura M, Kase Y, et al: Early detection of the Limulus ame-bocyte lysate reaction evoked by endotoxins. Anal Biochem 2008; 373:281-286
22. Rios-Santos F, Benjamim CF, Zavery D, et al: A critical role of leukotri-ene B4 in neutrophil migration to infectious focus in cecal ligation and puncture sepsis. Shock 2003; 19:61-65
23. Adib-Conquy M, Cavaillon JM: Compensatory anti-infammatory response syndrome. Thromb Haemost 2009; 101:36-47
24. Muenzer JT, Davis CG, Chang K, et al: Characterization and modulation of the immunosuppressive phase of sepsis. Infect Immun 2010; 78:1582-1592
25. Kasten KR, Prakash PS, Unsinger J, et al: Interleukin-7 (IL-7) treatment accelerates neutrophil recruitment through gamma delta T-cell IL-17 production in a murine model of sepsis. Infect Immun 2010; 78:4714-4722
26. Craciun FL, Schuller ER, Remick DG: Early enhanced local neutrophil recruitment in peritonitis-induced sepsis improves bacterial clearance and survival. J Immunol 2010; 185:6930-6938
27. Clish CB, O'Brien JA, Gronert K, et al: Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. Proc Natl Acad Sci USA 1999; 96:8247-8252
28. Godson C, Mitchell S, Harvey K, et al: Cutting edge: Lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J Immunol 2000; 164:1663-1667
29. Chiang N, Fredman G, Bäckhed F, et al: Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature 2012; 484:524-528
30. Prescott D, McKay DM: Aspirin-triggered lipoxin enhances macrophage phagocytosis of bacteria while inhibiting infammatory cytokine production. Am J Physiol Gastrointest Liver Physiol 2011; 301:G487-G497
31. Campbell EL, Serhan CN, Colgan SP: Antimicrobial aspects of infammatory resolution in the mucosa: A role for proresolving mediators. J Immunol 2011; 187:3475-3481
32. Fisher CJ Jr, Dhainaut JF, Opal SM, et al: Recombinant human interleu-kin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994; 271:1836-1843
33. Abraham E, Wunderink R, Silverman H, et al: Effcacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, mul-ticenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 1995; 273:934-941
34. Blackwell TS, Christman JW: Sepsis and cytokines: Current status. Br J Anaesth 1996; 77:110-117
35. Remick DG, Bolgos G, Copeland S, et al: Role of interleukin-6 in mortality from and physiologic response to sepsis. Infect Immun 2005; 73:2751-2757
36. Bossink AW, Paemen L, Jansen PM, et al: Plasma levels of the che-mokines monocyte chemotactic proteins-1 and-2 are elevated in human sepsis. Blood 1995; 86:3841-3847
37. Leeson MC, Morrison DC: Induction of proinfammatory responses in human monocytes by particulate and soluble forms of lipopolysac-charide. Shock 1994; 2:235-245
38. Hemmi H, Takeuchi O, Kawai T, et al: A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408:740-745
39. Sparwasser T, Miethke T, Lipford G, et al: Bacterial DNA causes septic shock. Nature 1997; 386:336-337
40. Kure I, Nishiumi S, Nishitani Y, et al: Lipoxin A(4) reduces lipopolysaccharide-induced infammation in macrophages and intestinal epithelial cells through inhibition of nuclear factor-kappaB activation. J Pharmacol Exp Ther 2010; 332:541-548
41. Maiti G, Naskar D, Sen M: The Wingless homolog Wnt5a stimulates phagocytosis but not bacterial killing. Proc Natl Acad Sci USA 2012; 109:16600-16605
42. Kim J, Kim J, Kim DW, et al: Wnt5a induces endothelial infammation via beta-catenin-independent signaling. J Immunol 2010; 185:1274-1282